logo
What exactly is in gas station weed?

What exactly is in gas station weed?

Edibles containing the psychoactive compound delta-8-THC, derived from federally legal hemp, are available even in some U.S. states where cannabis remains banned—although they are not FDA-approved. Photographs by Rebecca Hale This article is part of The New Cannabis, a National Geographic exploration into the most critical questions raised by today's stronger, stranger, ever more accessible weed. Learn more.
Though the term is widely used in today's cannabis culture, synthetic marijuana is a bit of a misnomer. The truth is, 'there's no such thing as synthetic marijuana or synthetic cannabis,' says Deepak Cyril D'Souza, professor of psychiatry at the Yale School of Medicine and director of the Yale Center for the Science of Cannabis and Cannabinoids. Usually people use synthetic marijuana to refer to a cannabis product that was derived from hemp and contains the psychoactive substance delta-8, or one that was produced from a series of compounds that were synthetically made in a lab (aka synthetic cannabinoids).
While both types of products mimic the effects of THC, the primary psychoactive compound in marijuana, 'synthetic cannabinoids are between 10 and 200 times more potent' than the usual THC in cannabis, D'Souza says.
Yet many people don't realize this, and synthetic cannabinoids are very easy to purchase. They are often sold at gas stations, bodegas, convenience stores, and smoke shops around the United States. And because of a loophole in federal law, which makes delta-8-THC legal (unlike delta-9-THC, the primary psychoactive compound in cannabis), teenagers can buy gummies, flavored vaping cartridges, and other delta-8-containing products right off the shelf. (Delta-8 tends to be less potent than delta-9 but still carries risks on its own.) A study last year found that 11 percent of high school seniors reported using delta-8. This selection of cannabis edibles contains both delta-8-THC and delta-9-THC. Synthesized delta-8 also comes in other forms, including vapes, tinctures, and smokable hemp flower. How delta-8 products differ from regular marijuana
Delta-9 creates the high that people typically experience from consuming cannabis. Delta-8 has psychoactive effects that are similar to those produced by delta-9, though delta-8 is naturally less potent.
While delta-9 continues to be illegal at the federal level, delta-8 is legal because of a loophole in the U.S. Agriculture Improvement Act of 2018, which legalized the cultivation and sale of hemp.
Though hemp and marijuana both come from the Cannabis sativa plant, they differ in their chemical composition, especially their concentration of delta-9. By definition, hemp may not contain a delta-9 concentration of more than 0.3 percent on a dry weight basis, whereas marijuana can contain significantly more.
Hemp also contains small amounts of delta-8. To get enough delta-8 for commercial products, manufacturers extract and convert CBD (cannabidiol, another compound naturally present in cannabis that is legal and nonintoxicating) from hemp to delta-8 in a lab, using chemicals such as sulfuric acid, hydrochloric acid, toluene, or heptane.
Despite delta-8 being legal on a federal level, some states have banned or severely restricted it in recent years, which puts its legal status in a gray area. Even so, delta-8 remains legal in more states than not, as well as in Washington, D.C.
Unlike products that contain delta-9, delta-8 products are not regulated by the U.S. Food and Drug Administration, which means that potency and purity can vary. There's also a risk they may contain undetected impurities from the environment or the conversion process, research has found. In fact, common contaminants in delta-8 products include residual solvents, pesticides, microbes, and heavy metals like lead, arsenic, and mercury, all of which may pose their own health risks, according to studies.
Meanwhile, there was a significant uptick in concerned calls from consumers to America's Poison Centers about experiences with delta-8, with an 82 percent increase from 2021 to 2022 (to 3,358 calls).
Even without the presence of impurities, delta-8 can have problematic effects, especially because many people are consuming it in high amounts since they view it as 'weed lite' or 'marijuana lite,' experts say.
'A lot of young people think delta-8 is not as potent as delta-9,' notes Akhil Anand, an addiction psychiatrist and clinical assistant professor at the Cleveland Clinic. 'But because of the lack of regulations, the way it's consumed, and the risk of contaminants and adulterants … people can become dependent or addicted.' Edibles, like this chocolate bar containing delta-8 and delta-9, make up the third largest segment of the legal U.S. cannabis market, behind flower and vaping products. K2, spice, and skunk: 'off-the-charts intoxicating'
Unlike delta-8, synthetic cannabinoids are a class of substances that are made in a lab and designed to mimic THC from cannabis. 'It's not really cannabis at all,' Anand says, because synthetic cannabinoids are entirely manufactured from chemicals.
Some of these synthetic products—with names like K2, spice, Scooby snacks, or skunk—are marketed in colorful packaging as herbal incense or potpourri, and they're often made by spraying synthetic compounds (such as naphthoylindoles, naphthylmethylindoles, phenylacetylindoles, and others with equally tongue-twisting names) onto dried plant material so it looks like cannabis, Anand says.
These products are not legal—when it comes to their manufacturing, sale, or consumption—at the federal level or the state level. In fact, many of these compounds have been banned by the federal government and classified as Schedule I controlled substances by the Drug Enforcement Administration. In recent years there have been several arrests and indictments of people involved in synthetic cannabinoid drug trafficking rings, including arrests this year related to a website-driven scheme to provide K2 and spice to people in prisons.
Because standard drug tests are designed to detect traditional THC, they won't detect synthetic cannabinoids. Not surprisingly, these products often appeal to people who are concerned about being tested for drugs such as those in the military, the federal government, or the prison system, D'Souza says.
A complicating factor: 'We can't test for these in the emergency department,' Anand explains, 'so it becomes challenging to treat these patients because we don't know what they have taken.' And the patients can't or won't tell emergency department doctors what they have taken because 'they're often not in the right state of mind,' Anand says.
Consuming synthetic cannabinoids can be dangerous. One review of studies found these products were responsible for a 'higher toxicity than THC and longer-lasting effects,' including increased risk of psychiatric disorders. And deaths have been linked to synthetic cannabinoids laced with chemicals found in rat poison.
In a study in the July 2025 issue of the journal Drug and Alcohol Dependence, researchers analyzed adverse effects associated with the use of synthetic cannabinoids, as reported in 49 published studies. The predominant ones involved the neurological and cardiovascular systems, with symptoms such as seizures, altered consciousness, tachycardia (rapid heart rate), and hypertension. Another 2025 study found that people with a dependence on synthetic cannabinoids exhibited more impulsivity and self-harming behaviors than their healthy peers. These products are especially risky for teens because their brains are still developing, D'Souza adds.
'These can be off-the-charts intoxicating because manufacturers are putting high concentrations in these products,' says Robert Welch, a pharmacist and director of the National Center for Cannabis Research and Education at the University of Mississippi. 'My advice is just to avoid this stuff because there's no way to know what you're taking.'
Besides being dangerous in their own right, these synthetic products take attention 'away from the health benefits that properly grown and sourced cannabis products can have,' Welch says. 'People don't understand the differences.' A version of this story appears in the September 2025 issue of National Geographic magazine.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Abbott Taps Growing TMVR Market With Tendyne System
Abbott Taps Growing TMVR Market With Tendyne System

Yahoo

timean hour ago

  • Yahoo

Abbott Taps Growing TMVR Market With Tendyne System

Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bagel Recall Update As FDA Issues Risk Warning
Bagel Recall Update As FDA Issues Risk Warning

Newsweek

time2 hours ago

  • Newsweek

Bagel Recall Update As FDA Issues Risk Warning

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A recall of bagels and pastries due to possible undeclared allergens has been issued the second-highest risk warning by the U.S. Food and Drug Administration. The Bonami Baking Company, Inc., based in California, issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared milk, wheat, eggs, and soy. The FDA later issued a Class II risk classification for the recall on August 13. Newsweek contacted the Bonami Baking Company, Inc. for comment by email outside of regular working hours. Stock image. The Bonami Baking Company, Inc. issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared allergens. Stock image. The Bonami Baking Company, Inc. issued a voluntary recall on July 24 for various bagel, bun and croissant products due potential undeclared allergens. Francis Chung/POLITICO/AP Why It Matters A Class II risk classification (one of three) refers to a situation in which the "use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," according to the FDA. Milk, wheat, eggs and soy are four of the nine major food allergens. The others are fish, crustacean shellfish, tree nuts, peanuts and sesame. Allergic reactions vary in severity from mild symptoms, such as hives and lip swelling, to life-threatening complications, such as anaphylaxis, that may include fatal respiratory problems. What To Know The products impacted by the recall are the following: Whole Grain Par Baked Jalapeno Cheddar Bagel - 192 cases (72 pieces/case) - undeclared milk Cheddar Bagel - 6,156 pieces - undeclared milk and wheat Chocolate Croissants - 21,096 pieces - undeclared wheat, milk, and soy Whole Wheat Chocolate Croissants - 351 cases (144 pieces/case) - undeclared milk and soy Wheat Hamburger Buns - 61,862 packages (12 dozen/package) - undeclared milk and/or eggs The products have use-by dates between 7/20/2025 and 7/20/2026. They were distributed to retail locations in California. As of August 13, there had been no reports of illnesses in connection to the consumption of the recalled products. What People Are Saying The FDA, on its website: "People with food allergies should read labels and avoid the foods they are allergic to. The law requires that food labels identify the food source of all major food allergens used to make the food." The Mayo Clinic, on its website: "Milk allergy is an atypical immune system response to milk and products containing milk. It's one of the most common food allergies in children. Cow's milk is the usual cause of milk allergy, but milk from sheep, goats, buffalo and other mammals also can cause a reaction. "An allergic reaction usually occurs soon after you or your child consumes milk. Signs and symptoms of milk allergy range from mild to severe and can include wheezing, vomiting, hives and digestive problems. Milk allergy can also cause anaphylaxis — a severe, life-threatening reaction." Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last five, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods." What Happens Next The recalls are listed as ongoing, according to the FDA. Consumers who have allergies or sensitives to milk, wheat, eggs and soy should not consume the recalled products.

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Yahoo

time4 hours ago

  • Yahoo

BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "BrainStorm remains focused on executing our clinical development plan for NurOwn®. We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We are also advancing key operational activities, including discussions with clinical sites as well as ongoing engagement with our selected CDMO partners to ensure readiness for clinical drug supply. We are encouraged by the ongoing interest and support from clinicians and the ALS community, and we remain confident that, if approved, NurOwn has the potential to make a meaningful difference for patients and their families." Mr. Lebovits continued, "We support the FDA's consideration of the Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence. We continue to stand behind the integrity and rigor of our data and will continue to engage with clinicians and the ALS community." Recent Highlights NurOwn (MSC-NTF) for ALS FDA has cleared the company to initiate the Phase 3b clinical trial of NurOwn® The Phase 3b trial, known as ENDURANCE, is expected to enroll approximately 200 participants at leading academic medical centers and will consist of a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension in which all participants will receive NurOwn. The primary endpoint is the change from baseline to week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R). Successful completion of the double blind portion of the study (Part A) is expected to generate the clinical data needed to support a new BLA submission. Details of the trial, including a list of anticipated participating clinical sites, are available on ID NCT06973629. A Citizens Petition submitted to the FDA by ALS Community requesting a new review of the NurOwn data The company acknowledges that the FDA's consideration of the petition provides a new opportunity to reaffirm NurOwn's potential as a therapy for ALS. BrainStorm was not involved in drafting or submitting this petition or its contents. New survival data from NurOwn Expanded Access Program show that 100% of participants (10/10) in the EAP survived more than 5 years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS would survive beyond 5 years. The single death in the cohort occurred following elective euthanasia. The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset. Although the EAP cohort included participants earlier in their disease course, these results are encouraging and support further study. Manufacturing Partnership with Minaris BrainStorm has signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, to manufacture NurOwn for the upcoming Phase 3b clinical trial. NurOwn® data selected as Breakthrough Science for Presentation at ISCT 2025 Meeting The new pharmacogenomic data were delivered in an oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting in May 2025, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were "carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies." Financial Results for the Second quarter Ended June 30, 2025 Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025. Research and development expenditures, net, for the quarter ended June 30, 2025 were $1.1 million, compared to $0.9 million for the quarter ended June 30, 2024. General and administrative expenses for the quarter ended June 30, 2025 were approximately $1.4 million, compared to approximately $2.1 million for the quarter ended June 30, 2024. Net loss for the quarter ended June 30, 2025, was approximately $2.9 million, as compared to a net loss of approximately $2.5.4 million for the quarter ended June 30, 2024. Net loss per share for the three months ended June 30, 2025, and 2024 was $0.34 and $0.60, respectively. Conference Call and Webcast Participant Numbers: Toll Free 877-545-0320 International 973-528-0002 Participant Access Code 601260 Webcast The replay of the conference call can be accessed by dialing the numbers below and will be available until August 28. Replay Numbers: Toll Free 877-481-4010 International 919-882-2331 Reply Passcode 52831 About NurOwn® The NurOwn® technology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company's proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection. NurOwn® is BrainStorm's lead investigational therapy for amyotrophic lateral sclerosis (ALS) and has received Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). A Phase 3 trial in ALS (NCT03280056) has been completed, and a second Phase 3b trial is set to launch under a Special Protocol Assessment (SPA) agreement with the FDA. The NurOwn clinical program has generated valuable insights into ALS disease biology, including pharmacogenomic response associated with the UNC13A genotype, biomarker data collected at seven longitudinal time points, and a comprehensive analysis of the "Floor Effect" — a critical challenge in measuring clinical outcomes in advanced ALS. BrainStorm has published its findings in multiple peer-reviewed journals. In addition to ALS, BrainStorm has completed a Phase 2 open-label multicenter trial (NCT03799718) of MSC-NTF cells in progressive multiple sclerosis (MS), supported by a grant from the National MS Society. BrainStorm is also advancing a proprietary, allogeneic exosome-based platform designed to deliver therapeutic proteins and nucleic acids. The company recently received a Notice of Allowance from the U.S. Patent and Trademark Office for a foundational patent covering its exosome technology, further strengthening BrainStorm's growing IP portfolio in this emerging area of regenerative medicine. To learn more, visit Notice Regarding Forward-Looking Statements This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties, including statements regarding meetings with the U.S. Food and Drug Administration (FDA), Special Protocol Assessment (SPA), the clinical development of NurOwn as a therapy for the treatment of ALS, the future availability of NurOwn to patients, and the future success of BrainStorm. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BrainStorm's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These potential risks and uncertainties include, without limitation, management's ability to successfully achieve its goals, BrainStorm's ability to raise additional capital, BrainStorm's ability to continue as a going concern, prospects for future regulatory approval of NurOwn, whether BrainStorm's future interactions with the FDA will have productive outcomes, and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations, and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. CONTACTS Investors:Michael WoodPhone: +1 646-597-6983mwood@ Media: Uri Yablonka, Chief Business OfficerPhone: +1 917-284-2911uri@ CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (Except share data) June 30,December 31, 20252024 UnauditedAudited U.S. $ in thousands ASSETSCurrent Assets: Cash and cash equivalents$ 824$ 187 Other accounts receivable 106 63 Prepaid expenses and other current assets 585 135 Total current assets$ 1,515$ 385Long-Term Assets: Prepaid expenses and other long-term assets $ 24$ 22 Restricted Cash 201 184 Operating lease right of use asset (Note 3) 495 807 Property and Equipment, Net 331 434 Total Long-Term Assets$ 1,051$ 1,447Total assets$ 2,566$ 1,832LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)Current Liabilities: Accounts payables$ 5,997$ 6,080 Accrued expenses 367 619 Short-term loans (Note 7) 101 300 Operating lease liability (Note 3) 381 549 Employees related liability 1,682 1,430 Total current liabilities$ 8,528$ 8,978Long-Term Liabilities: Operating lease liability (Note 3) 95 171 Warrants liability (Note 4) - 447 Total long-term liabilities$ 95$ 618Total liabilities$ 8,623$ 9,596Stockholders' Deficit: Stock capital: (Note 5) 16 14 Common Stock of $0.00005 par value - Authorized: 250,000,000 shares at June 30, 2025 and at December 31, 2024 respectively; Issued and outstanding: 10,120,109 and 6,141,762 shares at June 30, 2025 and December 31, 2024 respectively Additional paid-in-capital 226,446 218,974 Treasury stocks (116) (116) Accumulated deficit (232,403) (226,636) Total stockholders' deficit$ (6,057)$ (7,764)Total liabilities and stockholders' deficit$ 2,566$ 1,832 BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) U.S. dollars in thousands (Except share data) Six months ended Three months ended June 30, June 30, 2025202420252024 UnauditedUnaudited Operating expenses:Research anddevelopment, net$ 2,424$ 1,883$ 1,120$ 922 General and administrative 3,238 3,573 1,453 2,060Operating loss (5,662) (5,456) (2,573) (2,982)Financial income (expense), net (284) 43 (330) 30Gain (loss) on change in fair value of Warrants liability (Note 4) 179 529 - (411)Net loss$ (5,767)$ (5,942)$ (2,903)$ (2,541)Basic and diluted net lossper share from continuing operations$ (0.77)$ (1.35)$ (0.34)$ (0.60)Weighted average numberof shares outstanding usedin computing basic and diluted net loss per share 7,487,495 4,531,801 8,620,400 4,747,699 Logo - View original content to download multimedia: SOURCE BrainStorm Cell Therapeutics Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store